December 15, 2025
To be a canary in the C> “gold” mine …
A Humpty-Dumpty, Capricor Therapeutics (CAPR) closed down Friday -$1.16 after Thursday’s -$1.49, Wednesday’s +$1.29, Tuesday’s -$1.18 and last Monday’s +$1.67. With more down side (-$) to follow! <see The Bottom Line>
Pre-open Signals: 8 Positive and 1 Negative Indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
December 12, 2025
Who is wasting lipstick on this pig?
WHO and WHAT is CONNING “American” investors re Harvard Apparatus RT (OTVQB: HRGN), a Beijing, China percentage “owned” and run company … Patterns of share pricing manipulation?
OTCQB: HRGN traded 12/11... +$0.12 with 4,615 shares traded after Thursday’s $0.00, Wednesday’s -$0.06 with 600 shares traded, Tuesday’s $0.00 with 600 shares traded and Monday’s (12/8) +$0.18 with 6,900 shares traded) – manipulating the downside, PONZI scheme?
Cash starved, NO clinical data after 5-year ago IND.
Accumulated deficit to date= $103.2 M in 12 years
U.S. investors BEWARE, forewarned is forearmed?
December 15, 2025
Rotation trade continues, with slim pickings in the Dow, S&P as Nasdaq drags deeper
RMi collects, curates, interprets and disseminates cell and gene therapy sector (C>) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision
It’s not always time to buy or sell; but it is time to KNOW and why!
Never leave an investor uninformed!
December 12, 2025
Who is wasting lipstick on this pig? WHO and WHAT is CONNING “American” investors re Harvard Apparatus RT (OTVQB: HRGN), a Beijing, China percentage “owned” and run company … Patterns of share pricing manipulation? OTCQB: HRGN traded 12/11... +$0.12 with 4,615 shares traded after Thursday’s $0.00, Wednesday’s -$0.06 with 600 shares traded, Tuesday’s $0.00 with 600 shares traded and Monday’s (12/8) +$0.18 with 6,900 shares traded) – manipulating the downside, PONZI scheme? Cash starved, NO clinical data after 5-year ago IND. Accumulated deficit to date= $103.2 M in 12 years U.S. investors BEWARE, forewarned is forearmed?
December 5, 2025
CAPR is trading +1.00 at $26.32 The offering to close on or about 12/8/25. CAPR believes these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position … clinical issues in the FDA’s Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.” However, there are significant execution and regulatory risks around Deramiocel, including shifting FDA guidance and development costs.
November 26, 2025
Give thanks for .... unknown blessings already on their way! Thanksgiving is possible only for those who take time ... to remember; no one can give thanks who has a short memory. There's more...
6 hours 54 min ago
RMi Closing Bell: Suck it up
15 hours 55 min ago
RMi Pre-opening: My choice
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
